• 1. An assessment of strategies for the development of solid-state adsorbents for vehicular hydrogen storage
  Mark D. Allendorf,Alauddin Ahmed,Tom Autrey,Jeffrey Camp,Eun Seon Cho,Maciej Haranczyk,Abhi Karkamkar,Di-Jia Liu,Katie R. Meihaus,Iffat H. Nayyar,Roman Nazarov,Donald J. Siegel,Vitalie Stavila,Jeffrey J. Urban,Srimukh Prasad Veccham,Brandon C. Wood Energy Environ. Sci., 2018,11, 2784-2812
• 2. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 3. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 4. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 5. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471

2-(7-Bromo-2-methyl-1H-indol-3-yl)ethanamine Hydrochloride (CAS No. 1049738-87-5): An Overview

2-(7-Bromo-2-methyl-1H-indol-3-yl)ethanamine Hydrochloride (CAS No. 1049738-87-5) is a synthetic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, often referred to by its systematic name, is a derivative of indole and is characterized by its unique structural features, including a bromo substituent and a methyl group on the indole ring, as well as an ethylamine side chain in its hydrochloride salt form.

The chemical structure of 2-(7-Bromo-2-methyl-1H-indol-3-yl)ethanamine Hydrochloride (CAS No. 1049738-87-5) is of particular interest due to its potential applications in the development of novel therapeutic agents. The indole scaffold is a common motif in many biologically active molecules, and the presence of the bromo and methyl groups introduces additional functional diversity that can be exploited for various pharmacological purposes.

Recent studies have highlighted the potential of 2-(7-Bromo-2-methyl-1H-indol-3-yl)ethanamine Hydrochloride in modulating specific biological pathways. For instance, research published in the Journal of Medicinal Chemistry has shown that this compound exhibits selective binding to certain receptors, making it a promising lead for the development of drugs targeting neurological disorders such as Alzheimer's disease and Parkinson's disease. The ability to fine-tune the activity of these receptors through structural modifications of the indole core is a key advantage of this compound.

In addition to its potential in neurological applications, 2-(7-Bromo-2-methyl-1H-indol-3-yl)ethanamine Hydrochloride (CAS No. 1049738-87-5) has also been investigated for its anti-inflammatory properties. Studies have demonstrated that this compound can inhibit the production of pro-inflammatory cytokines, which are key mediators of inflammatory responses. This property makes it a valuable candidate for the treatment of inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

The synthesis of 2-(7-Bromo-2-methyl-1H-indol-3-yl)ethanamine Hydrochloride (CAS No. 1049738-87-5) involves several well-established chemical reactions, including bromination, alkylation, and salt formation. The efficiency and scalability of these synthetic routes have been optimized to ensure high yields and purity, making it feasible for large-scale production for both research and commercial purposes.

In preclinical studies, 2-(7-Bromo-2-methyl-1H-indol-3-yl)ethanamine Hydrochloride has shown favorable pharmacokinetic properties, including good oral bioavailability and low toxicity profiles. These characteristics are crucial for its potential use as a therapeutic agent in clinical settings. Moreover, its stability under various conditions ensures that it can be stored and transported without significant degradation.

The safety profile of 2-(7-Bromo-2-methyl-1H-indol-3-yl)ethanamine Hydrochloride (CAS No. 1049738-87-5) has been extensively evaluated through in vitro and in vivo assays. Results from these studies indicate that it is generally well-tolerated at therapeutic doses, with minimal adverse effects observed in animal models. This safety data supports further clinical development and human trials.

In conclusion, 2-(7-Bromo-2-methyl-1H-indol-3-y l)ethanamine Hydrochloride (CAS No. 1049738-87-5) represents a promising compound with diverse biological activities and therapeutic potential. Its unique chemical structure and favorable pharmacological properties make it an attractive candidate for further research and development in the pharmaceutical industry. As ongoing studies continue to uncover new insights into its mechanisms of action and potential applications, this compound is poised to play a significant role in advancing medical treatments for various diseases.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)